145 related articles for article (PubMed ID: 24879564)
1. Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer.
Thompson PA; Ljuslinder I; Tsavachidis S; Brewster A; Sahin A; Hedman H; Henriksson R; Bondy ML; Melin BS
Cancer Res; 2014 Jun; 74(11):2928-35. PubMed ID: 24879564
[TBL] [Abstract][Full Text] [Related]
2. LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.
Faraz M; Tellström A; Ardnor CE; Grankvist K; Huminiecki L; Tavelin B; Henriksson R; Hedman H; Ljuslinder I
BMC Cancer; 2020 May; 20(1):459. PubMed ID: 32448168
[TBL] [Abstract][Full Text] [Related]
3. Increased copy number at 3p14 in breast cancer.
Ljuslinder I; Malmer B; Golovleva I; Thomasson M; Grankvist K; Höckenström T; Emdin S; Jonsson Y; Hedman H; Henriksson R
Breast Cancer Res; 2005; 7(5):R719-27. PubMed ID: 16168117
[TBL] [Abstract][Full Text] [Related]
4. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
5. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.
Krig SR; Frietze S; Simion C; Miller JK; Fry WH; Rafidi H; Kotelawala L; Qi L; Griffith OL; Gray JW; Carraway KL; Sweeney C
Mol Cancer Res; 2011 Oct; 9(10):1406-17. PubMed ID: 21821674
[TBL] [Abstract][Full Text] [Related]
6. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
7. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
8. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
9. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?
Hedman H; Nilsson J; Guo D; Henriksson R
Acta Oncol; 2002; 41(4):352-4. PubMed ID: 12234026
[TBL] [Abstract][Full Text] [Related]
10. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
Morrison MM; Williams MM; Vaught DB; Hicks D; Lim J; McKernan C; Aurisicchio L; Ciliberto G; Simion C; Sweeney C; Cook RS
Oncogene; 2016 Mar; 35(9):1143-52. PubMed ID: 26148232
[TBL] [Abstract][Full Text] [Related]
11. Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer.
Ljuslinder I; Golovleva I; Henriksson R; Grankvist K; Malmer B; Hedman H
Breast Cancer Res; 2009; 11(3):403. PubMed ID: 19490591
[No Abstract] [Full Text] [Related]
12. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
13. LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.
Sheu JJ; Lee CC; Hua CH; Li CI; Lai MT; Lee SC; Cheng J; Chen CM; Chan C; Chao SC; Chen JY; Chang JY; Lee CH
Oncogene; 2014 Mar; 33(11):1375-84. PubMed ID: 23624915
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
Sugano T; Yoshida M; Masuda M; Ono M; Tamura K; Kinoshita T; Tsuda H; Honda K; Gemma A; Yamada T
Br J Cancer; 2020 Jun; 122(12):1811-1817. PubMed ID: 32265507
[TBL] [Abstract][Full Text] [Related]
15. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.
Liu Y; Zhou R; Baumbusch LO; Tsavachidis S; Brewster AM; Do KA; Sahin A; Hortobagyi GN; Taube JH; Mani SA; Aarøe J; Wärnberg F; Børresen-Dale AL; Mills GB; Thompson PA; Bondy ML
Breast Cancer Res Treat; 2014 Jan; 143(1):189-201. PubMed ID: 24305980
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients.
Li Z; Moore DH; Meng ZH; Ljung BM; Gray JW; Dairkee SH
Cancer Res; 2002 Feb; 62(4):1000-3. PubMed ID: 11861372
[TBL] [Abstract][Full Text] [Related]
18. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.
Thompson PA; Brewster AM; Kim-Anh D; Baladandayuthapani V; Broom BM; Edgerton ME; Hahn KM; Murray JL; Sahin A; Tsavachidis S; Wang Y; Zhang L; Hortobagyi GN; Mills GB; Bondy ML
PLoS One; 2011; 6(8):e23543. PubMed ID: 21858162
[TBL] [Abstract][Full Text] [Related]
19. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.
Hedman H; Lindström AK; Tot T; Stendahl U; Henriksson R; Hellberg D
Acta Oncol; 2010 Aug; 49(6):812-5. PubMed ID: 20553099
[TBL] [Abstract][Full Text] [Related]
20. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
